Sep 15, 2026, 2:51 PMHealthcare
Shingrix Studies Suggest Lower Heart Risk and Delayed Dementia
Research increasingly links Shingrix vaccination to lower heart-disease risk and delayed dementia, but the MarketWatch summary provides limited detail.
Listen to this briefingAudio briefing
Summary
MarketWatch reported on September 15, 2026, that a growing body of research suggests the shingles vaccine Shingrix may reduce heart-disease risk and delay dementia. The feed gave no numerical risk reductions, study names, sample sizes, patient groups or research dates.
These reported cardiovascular and cognitive associations could make Shingrix relevant beyond shingles, but the source provided only a one-sentence summary and did not establish causation. It also did not identify a manufacturer, public company, regulatory filing or next research milestone.
Positives
- A growing body of research links Shingrix with reduced heart-disease risk.
- Research also suggests Shingrix may delay dementia.
- Two distinct outcome areas, cardiovascular disease and dementia, are associated with Shingrix in the reported research.
Risks & concerns
- The findings are described as suggestive rather than conclusive or causal.
- The feed provided no effect estimates, study designs, sample sizes or patient demographics.
- No safety findings, researcher names, published studies or follow-up milestones were disclosed.
- The limited source did not identify Shingrix’s manufacturer or any publicly traded company.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/is-the-shingles-vaccine-the-secret-to-living-longer-and-delaying-dementia-heres-what-the-science-says-1c108c26?mod=mw_rss_topstories
Read full article
